연구동향 분석

EDITORIAL : Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?

( Seung Ki Kwok ) 2014년

논문상세정보
    • 저자 ( Seung Ki Kwok )
    • 제어번호 100119887
    • 학술지명 The Korean Journal of Internal Medicine
    • 권호사항 Vol. 29 No. 5 [ 2014 ]
    • 발행처 대한내과학회
    • 발행처 URL http://www.kaim.or.kr
    • 자료유형 학술저널
    • 수록면 577-579 ( 3쪽)
    • 언어 Korean
    • 출판년도 2014
    • 등재정보 KCI등재
    • 판매처 한국학술정보
    유사주제 논문( 0)
인용/피인용

' EDITORIAL : Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?' 의 참고문헌

  • Tofacitinib versus methotrexate in rheumatoid arthritis
    Lee EB N Engl J Med 370 : 2377 ~ 2386 - [2014]
  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
    van Vollenhoven RF N Engl J Med 367 : 508 ~ 519 [2012]
  • Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Tanaka Y Arthritis Care Res (Hoboken) 63 : 1150 ~ 1158 - [2011]
  • Rheumatoid arthritis: pathophysiology and implications for therapy
    Harris ED Jr N Engl J Med 322 : 1277 ~ 1289 [1990]
  • Prevention of organ allograft rejection by a specific Janus kinase 3inhibitor
    Changelian PS Science 302 : 875 ~ 878 - [2003]
  • Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Fleischmann R N Engl J Med 367 : 495 ~ 507 - [2012]
  • Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Fleischmann R Arthritis Rheum 64 : 617 ~ 629 - [2012]
  • FDA approves tofacitinib for rheumatoid arthritis
    Traynor K Am J Health Syst Pharm 69 : 2120 ~ [2012]
  • Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
    송관규 The Korean Journal of Internal Medicine 29 (5) : 656 ~ 663 [2014]
  • A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Kremer JM Arthritis Rheum 64 : 970 ~ 981 - [2012]